secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001193125-25-113820
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially
--------------------------------------------------------------------------------

- Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).
- Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.
- Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.
- Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.
- FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/0001193125-25-113820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/d821404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-113820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer